Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates.

ABSTRACT:

Background

A new promising therapeutic approach has emerged for patients chronically infected by the hepatitis B virus (HBV) with the development of a non-replicative adenovirus vector vaccine candidate (Ad-HBV). The vaccine encodes a fusion protein composed of a truncated HBV core protein, mutated polymerase protein, and two envelope domains. In this study, we assessed the immunogenicity of Ad-HBV administered to cynomolgus monkeys during a non-clinical safety assessment.

Methods

The virus was subcutaneously administered at 1.0 × 10⁹ viral particles (VP)/animal (low-dose group), 1.0 × 10¹⁰ VP/animal (mid-dose group), and 1.0 × 10¹¹ VP/animal (high-dose group); the control groups were administered an Ad5-null virus (1.0 × 10¹¹ VP/a

SUBMITTER: Zhang X 

PROVIDER: S-EPMC6056916 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature